Ignite Creation Date:
2024-05-06 @ 10:26 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03256721
Status:
TERMINATED
Last Update Posted:
2021-02-08
First Post:
2017-08-16
Brief Title:
Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
Sponsor:
Fuzhou General Hospital
Organization:
Fuzhou General Hospital
Study Overview
Official Title:
A Randomized Parallel Control Exploratory Trial to Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in Subjects With Advanced or Metastatic of the Non-small Cell Lung Cancer NSCLC
Status:
TERMINATED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to the enrollment was slow and exceeded the expected enrollment time
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Apatinib a novel targeted inhibitor of VEGF receptor 2 VEGFR2 shows significant antitumor activity in the patients with GC The purpose of this study is to determine whether apatinib plus chemotherapy drug can improve progression free survival compared with chemotherapy drug in patients with metastatic the non-small cell lung cancer who failed one lines of chemotherapy
Detailed Description:
Lung cancer is the leading cause of cancer death in world wild especially non-small cell lung cancer NSCLC Detection and early intervention are difficult because pathogenesis of NSCLC is not yet entirely clearMost of them are advanced or metastatic patients so approach 34 NSCLC undergo chemotherapy Fewer treatment options exist on NSCLC whom is wild type of EGFR The patient did not benefit from the existing treatment regimen after first-line treatment There is currently no effective drug to treat this group of patients
Apatinib a novel targeted inhibitor of VEGF receptor 2 VEGFR2 shows significant antitumor activity in the patients with GC The purpose of this study is to determine whether apatinib plus chemotherapy drug can improve progression free survival compared with chemotherapy drug in patients with metastatic the non-small cell lung cancer who failed one lines of chemotherapy
Apatinib a novel targeted inhibitor of VEGF receptor 2 VEGFR2 shows significant antitumor activity in the patients with GC The purpose of this study is to determine whether apatinib plus chemotherapy drug can improve progression free survival compared with chemotherapy drug in patients with metastatic the non-small cell lung cancer who failed one lines of chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None